Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: goldworldnet who wrote (251569)	5/24/2008 3:22:40 PM
From: mistermj	Read Replies (2) \| Respond to of 793797

Autopsy data suggests nearly all of us have small tumors. The only question is "if" the switch gets turned on. Dr. Judah Folkman did some fascinating research in this area of keeping tumors dormant by cutting off their blood supply. ======================== Most cancers, by the time they are diagnosed, have been growing for five to 10 years. Furthermore, autopsy data from automobile accident fatalities suggests that nearly all individuals carry "cancer without disease"—small, pinpoint in situ dormant tumors. Most of these tumors have high proliferation rates balanced by a high rate of apoptosis, and are nonangiogenic, so they have not yet developed a supporting system of blood vessels. Dormant tumors are quite common. For example, 39% of women over 40 carry a small breast carcinoma, but only one out of 100 will go on to develop apparent breast cancer in her lifetime. Nearly half of all men autopsied have small, dormant prostate cancers but only 1% would be expected to develop the disease. Amazingly, 98% of Canadians, Americans, and Europeans have more than one in situ thyroid carcinoma but only one out of 1000 will ever develop thyroid cancer. Clearly, a promising area of cancer therapy is to induce or prolong tumor dormancy in individuals destined to develop malignancies. There are several ways to do this, as suggested by leading animal models, including by immunization, hormonal deprivation, altered signaling pathways, and antiangiogenic strategies. nyas.org